Accurate and sensitive quantitation of N7-methyldeoxyguanosine-3'-monophosphate by 32P-postlabeling and storage-phosphor imaging.

2.50
Hdl Handle:
http://hdl.handle.net/10541/95248
Title:
Accurate and sensitive quantitation of N7-methyldeoxyguanosine-3'-monophosphate by 32P-postlabeling and storage-phosphor imaging.
Authors:
Haque, Kemal; Cooper, Donald P; Van Delft, J H; Lee, Siow Ming; Povey, Andrew C
Abstract:
As N7-methyldeoxyguanosine-3'-monophosphate (N7-MedGp) is the major, persistent DNA lesion generated by methylating agents, a combined HPLC/32P-postlabeling assay has been developed to quantitate this adduct in human DNA. N7-MedGp was purified from normal nucleotides by anion-exchange chromatography followed by reverse-phase HPLC procedures. The adduct was then 32P-postlabeled and resolved by two-dimensional TLC for detection and quantitation by storage-phosphor imaging. The effect of conditions used for DNA purification and digestion on the recovery of N7-MedGp has been investigated. Extended, raised temperature incubations normally employed during DNA purification were demonstrated to result in considerable loss of adduct through depurination after 22 h at 65 and 37 degrees C (82% and 20% loss, respectively), but depurination was reduced to 5% if the incubation was performed at either 4 or 22 degrees C. Similarly, close to optical recovery (83%) of N7-MedGp was achieved after DNA digestion by incubating at 4 degrees C, pH 7.4, for 18 h in the presence of micrococcal nuclease and calf spleen phosphodiesterase from Sigma and Boehringer Mannheim, respectively. Overall, the recovery of N7-MedGp was 40%, resulting in a detection limit of 1.3 fmol which is equivalent to 0.16 mumol of adduct/mol of 2'-deoxyguanosine-3'-monophosphate (dGp) when analyzing 10 micrograms of DNA. The N7-MedGp content of DNA that had been methylated in vitro using 0, 16, and 80 microM N-methyl-N-nitrosourea (NMU) was determined by 32P-postlabeling to be 12, 112, and 671 mumol of N7-MedGp/mol of dGp. Electrochemical detection of N7-methylguanine (N7-MeG) after HPLC purification measured approximately 2-fold higher levels, i.e., 25, 225, and 1080 mumol of N7-MeG/mol of Gua, at each NMU concentration, respectively. The levels of N7-MedGp in the white blood cell (WBC) DNA of patients receiving a single dose of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) chemotherapy were determined by 32P-postlabeling. Maximum levels were found 4-6 h after treatment, and in two out of four individuals adduct levels were decreased by 21 h. Prior to treatment, N7-MedGp was detectable in WBC DNA in two out of the four individuals indicating that nontherapeutic exposure to methylating agents had occurred.
Affiliation:
Cancer Research Campaign Department of Carcinogenesis and Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, U.K.
Citation:
Accurate and sensitive quantitation of N7-methyldeoxyguanosine-3'-monophosphate by 32P-postlabeling and storage-phosphor imaging. 1997, 10 (6):660-6 Chem. Res. Toxicol.
Journal:
Chemical Research in Toxicology
Issue Date:
Jun-1997
URI:
http://hdl.handle.net/10541/95248
DOI:
10.1021/tx9601723
PubMed ID:
9208172
Type:
Article
Language:
en
ISSN:
0893-228X
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorHaque, Kemalen
dc.contributor.authorCooper, Donald Pen
dc.contributor.authorVan Delft, J Hen
dc.contributor.authorLee, Siow Mingen
dc.contributor.authorPovey, Andrew Cen
dc.date.accessioned2010-03-30T13:54:58Z-
dc.date.available2010-03-30T13:54:58Z-
dc.date.issued1997-06-
dc.identifier.citationAccurate and sensitive quantitation of N7-methyldeoxyguanosine-3'-monophosphate by 32P-postlabeling and storage-phosphor imaging. 1997, 10 (6):660-6 Chem. Res. Toxicol.en
dc.identifier.issn0893-228X-
dc.identifier.pmid9208172-
dc.identifier.doi10.1021/tx9601723-
dc.identifier.urihttp://hdl.handle.net/10541/95248-
dc.description.abstractAs N7-methyldeoxyguanosine-3'-monophosphate (N7-MedGp) is the major, persistent DNA lesion generated by methylating agents, a combined HPLC/32P-postlabeling assay has been developed to quantitate this adduct in human DNA. N7-MedGp was purified from normal nucleotides by anion-exchange chromatography followed by reverse-phase HPLC procedures. The adduct was then 32P-postlabeled and resolved by two-dimensional TLC for detection and quantitation by storage-phosphor imaging. The effect of conditions used for DNA purification and digestion on the recovery of N7-MedGp has been investigated. Extended, raised temperature incubations normally employed during DNA purification were demonstrated to result in considerable loss of adduct through depurination after 22 h at 65 and 37 degrees C (82% and 20% loss, respectively), but depurination was reduced to 5% if the incubation was performed at either 4 or 22 degrees C. Similarly, close to optical recovery (83%) of N7-MedGp was achieved after DNA digestion by incubating at 4 degrees C, pH 7.4, for 18 h in the presence of micrococcal nuclease and calf spleen phosphodiesterase from Sigma and Boehringer Mannheim, respectively. Overall, the recovery of N7-MedGp was 40%, resulting in a detection limit of 1.3 fmol which is equivalent to 0.16 mumol of adduct/mol of 2'-deoxyguanosine-3'-monophosphate (dGp) when analyzing 10 micrograms of DNA. The N7-MedGp content of DNA that had been methylated in vitro using 0, 16, and 80 microM N-methyl-N-nitrosourea (NMU) was determined by 32P-postlabeling to be 12, 112, and 671 mumol of N7-MedGp/mol of dGp. Electrochemical detection of N7-methylguanine (N7-MeG) after HPLC purification measured approximately 2-fold higher levels, i.e., 25, 225, and 1080 mumol of N7-MeG/mol of Gua, at each NMU concentration, respectively. The levels of N7-MedGp in the white blood cell (WBC) DNA of patients receiving a single dose of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) chemotherapy were determined by 32P-postlabeling. Maximum levels were found 4-6 h after treatment, and in two out of four individuals adduct levels were decreased by 21 h. Prior to treatment, N7-MedGp was detectable in WBC DNA in two out of the four individuals indicating that nontherapeutic exposure to methylating agents had occurred.en
dc.language.isoenen
dc.subject.meshAnimals-
dc.subject.meshAutoradiography-
dc.subject.meshChromatography, High Pressure Liquid-
dc.subject.meshDNA-
dc.subject.meshDNA Adducts-
dc.subject.meshDeoxyguanine Nucleotides-
dc.subject.meshHumans-
dc.subject.meshImage Processing, Computer-Assisted-
dc.subject.meshIsotope Labeling-
dc.subject.meshPhosphorus Radioisotopes-
dc.subject.meshRadiographic Image Enhancement-
dc.subject.meshReproducibility of Results-
dc.subject.meshSensitivity and Specificity-
dc.titleAccurate and sensitive quantitation of N7-methyldeoxyguanosine-3'-monophosphate by 32P-postlabeling and storage-phosphor imaging.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Carcinogenesis and Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, U.K.en
dc.identifier.journalChemical Research in Toxicologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.